Wednesday, November 30, 2022
MARY KAY’S PROJECT FEATURED IN ECONOMIST IMPACT'S WORLD OCEAN SUMMIT IN SINGAPORE
ECO EXPO ASIA 2022 IN HONG KONG TO FOCUS ON DECARBONISING TECH
Tuesday, November 29, 2022
NIPPON EXPRESS SHOWCASES RANGE OF SERVICES, PRODUCTS AT CIIE IN SHANGHAI
Wednesday, November 23, 2022
CLARITAS HEALTHTECH EXPANDS GLOBAL PRESENCE WITH INDIA OPERATIONS FOCUSING ON MEDICAL IMAGE ENHANCEMENT AND AI ASSISTED DIAGNOSTIC TOOLS
LONDON and SINGAPORE, Nov 22 (Bernama-GLOBE NEWSWIRE) -- Claritas HealthTech (“Claritas”), a healthcare technology company specializing in advanced medical image enhancement and AI assisted diagnostic tools to aid and optimize the diagnostic workflow of clinicians, announces today it has selected Bengaluru in Karnataka as its base for its Indian business headquarters.
With an established presence in Singapore and a successful entry into the UK market, Claritas has selected Bengaluru as its base for India, to meet the vast and rapidly growing medical diagnostic requirements of the country. Mr. Chetan Baxi, Co-founder, and Director of Claritas, commented, “In the last two quarters this year, we have had strong demand from India for our technology that aids clinicians to interpret medical images with greater accuracy and efficiency. To meet this demand, and given the favourable market conditions, we have opted to establish an India unit dedicated to serving the Indian market. We expect these operations to commence by January 2023.”As part of its global deployment initiative, Claritas will introduce its suite of products, including, iRAD™ for radiology image enhancement, iPET™ for PET and PET-CT/MRI accelerated acquisition and enhancement, and its suite of AI diagnostic tools, to meet the demand from the Indian health sector.
Mr. Baxi added, "India holds significant demand in-country for our products that improve diagnostic workflow without increasing capital or operating costs. Claritas enables customers to significantly improve patient care while improving productivity of their imaging and diagnostic departments."
Locatory.com seeing steady growth, set to meet aviation industry needs
KUALA LUMPUR, Nov 22 (Bernama) -- Locatory.com, one of the world’s leading premium aircraft parts marketplaces, has been seeing steady growth for over a few years now, driven by the increase in clientele interest, driven by the continuous expansion of spare parts database.
Chief executive officer, Toma Matutyte said the company has continued to expand its spare parts database, which has been growing by 15 per cent per month.
“With cost optimisation and sustainability on everyone’s mind, the secondary aviation parts market is becoming an increasingly attractive opportunity.
“In 2022, we have received five times more requests for quotes compared to last year and are expecting this trend to continue into the next year,” she said in a statement today.
Being a tool for the simplified procurement of spare parts, Locatory.com, a family member of Avia Solutions Group, is deeply invested in the digitalisation of the process.
“Our mission is to connect aircraft parts’ buyers and sellers via an innovative platform that enables our customers to find, buy and sell aircraft parts or repair services in commercial, original equipment manufacturer, maintenance, repair and overhaul, military and general aviation segments across the globe.
“We have a truly global team, with people from over 10 countries sharing ideas and expertise in improving the company. We have been steadily expanding by around 15 per cent each month and there are no plans of slowing down,” added Matutyte.
-- BERNAMA
Thursday, November 10, 2022
Tessa Therapeutics seals exclusive agreement with Baylor College of Medicine
KUALA LUMPUR, Nov 8 (Bernama) -- Tessa Therapeutics Limited (Tessa), a clinical-stage cell therapy company has announced the execution of an exclusive agreement with Baylor College of Medicine for worldwide commercial rights to the allogeneic Epstein-Barr virus specific T-cell (EBVST) technology platform.
The platform is jointly developed by Tessa’s Scientific Co-Founder, Malcolm Brenner, M.D., Ph.D., and his colleagues Cliona Rooney Ph.D. and Helen Heslop M.D., D.Sc. at Baylor College of Medicine.
Tessa’s President and Chief Executive Officer, Thomas Willemsen, said in a statement: “Securing exclusive worldwide commercial rights for therapies developed using the EBVST platform is an important value driver for Tessa as we continue to advance TT11X as a potential treatment for CD30-positive lymphomas, while exploring opportunities to extend the technology to other cancer indications, including solid tumours.”
Tessa is currently advancing a pipeline of products that utilise CD30.CAR-modified EBVSTs, including its lead allogeneic cell therapy, TT11X, which is being co-developed for the treatment of relapsed or refractory CD30-positive lymphomas.
Clinical data from an ongoing Phase 1 study of TT11X in CD30-positive lymphomas (BESTA) has demonstrated a favourable safety profile and encouraging signs of efficacy with clinical responses observed in seven of nine patients.
TT11X was recently recognised in the “Most Promising Off-the-Shelf Therapies” category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022.
-- BERNAMA
Saturday, November 5, 2022
TRIANGLE LIFE NAMES JON HACK AS BOARD CHAIRMAN
management team. Niall and the rest of the team have identified a significant market opportunity and have built the company needed to respond to this need.